Stocks and Investing Stocks and Investing
Mon, November 27, 2023
Fri, November 24, 2023
Wed, November 22, 2023
Tue, November 21, 2023

Brian Abrahams Reiterated (SRPT) at Buy and Held Target at $148 on, Nov 21st, 2023


Published on 2024-10-28 07:42:09 - WOPRAI, Brian Abrahams
  Print publication without navigation


Brian Abrahams of RBC Capital, Reiterated "Sarepta Therapeutics, Inc." (SRPT) at Buy and Held Target at $148 on, Nov 21st, 2023.

Brian has made no other calls on SRPT in the last 4 months.



There are 6 other peers that have a rating on SRPT. Out of the 6 peers that are also analyzing SRPT, 1 agrees with Brian's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Kristen Kluska of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $80 on, Thursday, November 2nd, 2023


These are the ratings of the 5 analyists that currently disagree with Brian


  • Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $141 on, Thursday, November 2nd, 2023
  • Gil Blum of "Needham" Maintained at Strong Buy with Increased Target to $93 on, Thursday, November 2nd, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $146 on, Tuesday, October 31st, 2023
  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $115 on, Tuesday, October 31st, 2023
  • Uy Ear of "Mizuho" Reiterated at Strong Buy and Held Target at $160 on, Tuesday, September 26th, 2023